60
Participants
Start Date
May 1, 2024
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2027
Cardonilizumab
Two cycles of Inductive therapy: nab-paclitaxel 250mg/ m2+cisplatin 75mg/ m2+Cardonilizumab 10mg/kg,ivgtt,3 weeks per cycle for 2 cycles
Chemoradiotherapy ±immunotherapy
"Chemoradiotherapy ± immunotherapy:~* PTV: 50-50.4Gy/1.8-2Gy/25-28fractions ②nab-paclitaxel 100mg+cisplatin 25mg/ m2, d1, every 7 days for 3-5 weeks ③Cardonilizumab 10mg/kg,ivgtt,3 weeks per cycle for 2 cycles"
Radical surgery
Surgery was evaluated after concurrent chemoradiotherapy according to patients willing and the surgeons' assessment. If patients were accessed with unresectable disease after radiotherapy or refused to receive surgery, Cardonilizumab would be administered for 2 years or until disease progression.
RECRUITING
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing
NOT_YET_RECRUITING
Anyang Cancer Hospital, Anyang
NOT_YET_RECRUITING
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER